Your browser doesn't support javascript.
Why participation in an international clinical trial platform matters during a pandemic? Launching REMAP-CAP in Japan.
Kamata, Kazuhiro; Jindai, Kazuaki; Ichihara, Nao; Saito, Hiroki; Kato, Hideaki; Kunishima, Hiroyuki; Shintani, Ayumi; Nishida, Osamu; Fujitani, Shigeki.
  • Kamata K; Department of General Internal Medicine, Aizu Medical Center, Fukushima Medical University, 21-2 Maeda, Kawahigashimachi Tanisawa, Aizuwakamatsu-city, Fukushima, 969-3492, Japan.
  • Jindai K; Department of Pediatrics, Graduate School of Medical and Dental Sciences, Niigata University, 1-757 Asahimachi-dori, Chuo-ku, Niigata, 951-8510, Niigata city, Japan.
  • Ichihara N; Department of Healthcare Epidemiology, School of Public Health, Kyoto University, Yoshida-konoe-cho, Sakyo-Ku, Kyoto-city, Kyoto, 606-8501, Japan. jindai.kazuaki.z15@kyoto-u.jp.
  • Saito H; Department of Healthcare Quality Assessment, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
  • Kato H; Department of Emergency and Critical Care Medicine, St. Marianna University School of Medicine, Yokohama City Seibu Hospital, 1197-1 Yasashicho, Asahi-ku, Yokohama-city, Kanagawa, 241-0811, Japan.
  • Kunishima H; Infection Prevention and Control Department, Yokohama City University Hospital, 3-9 Fukuura, Kanazawa-ku, Yokohama-city, Kanagawa, 236-0004, Japan.
  • Shintani A; Department of Infectious Diseases, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki-city, Kanagawa, 216-8511, Japan.
  • Nishida O; Department of Medical Statistics, Graduate School of Medicine, Osaka City University, 1-4-3 Asahi-machi, Abeno-ku, Osaka-City, Osaka, 545-0051, Japan.
  • Fujitani S; Department of Anesthesiology and Critical Care Medicine, School of Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake-city, Aichi, 470-1192, Japan.
J Intensive Care ; 9(1): 34, 2021 Apr 14.
Article in English | MEDLINE | ID: covidwho-1183584
ABSTRACT
REMAP-CAP, a randomized, embedded, multifactorial adaptive platform trial for community-acquired pneumonia, is an international clinical trial that is rapidly expanding its scope and scale in response to the COVID-19 pandemic. Japan is now joining REMAP-CAP with endorsement from Japanese academic societies. Commitment to REMAP-CAP can significantly contribute to population health through timely identification of optimal COVID-19 therapeutics. Additionally, it will promote the establishment of a national and global network of clinical trials to tackle future pandemics of emerging and re-emerging infectious diseases, in collaboration with multiple stakeholders, including front-line healthcare workers, governmental agencies, regulatory authorities, and academic societies.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Language: English Journal: J Intensive Care Year: 2021 Document Type: Article Affiliation country: S40560-021-00547-7

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Language: English Journal: J Intensive Care Year: 2021 Document Type: Article Affiliation country: S40560-021-00547-7